Physician profile
Catherine Rivera
NPI 1376177550
$1,339.53
in general payments reported to CMS, 2019-2025
18 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $114 · 2023: $389 · 2024: $306 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.10 |
| Education | $265.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $345.54 | 2023-2024 | Padcev, Myrbetriq |
| Janssen Biotech, INC. | $158.34 | 2022-2025 | Erleada, Akeega, Rybrevant |
| Janssen Scientific Affairs, LLC | $149.52 | 2024-2025 | Erleada, Akeega, Balversa |
| Seagen INC. | $124.99 | 2021 | |
| Sumitomo Pharma America, INC. | $95.85 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $91.57 | 2024-2025 | Enhertu, Lynparza |
| Daiichi Sankyo INC. | $84.54 | 2024-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $61.23 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $44.97 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Caris Mpi, INC. | $25.00 | 2025 | Mi Cancer Seek |
| Eisai INC. | $24.48 | 2024 | |
| Blue Earth Diagnostics | $23.93 | 2025 | Posluma |
| Lilly USA, LLC | $23.33 | 2025 | Verzenio |
| Puma Biotechnology, INC. | $22.48 | 2024 | |
| Beone Medicines USA, INC. | $17.16 | 2025 | Tevimbra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.13 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $17.10 | 2022 | |
| Amgen INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.